Muscle wasting associated with the long-term use of mTOR inhibitors

  • Authors:
    • Bishal Gyawali
    • Tomoya Shimokata
    • Kazunori Honda
    • Chihiro Kondoh
    • Naomi Hayashi
    • Yasushi Yoshino
    • Naoto Sassa
    • Yasuyuki Nakano
    • Momokazu Gotoh
    • Yuichi Ando
  • View Affiliations

  • Published online on: September 13, 2016     https://doi.org/10.3892/mco.2016.1015
  • Pages: 641-646
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Some targeted therapies alter muscle mass due to interference with pathways of muscle metabolism. The effects of mammalian target of ra pamycin (mTOR) inhibitors on muscle mass have yet to be fully elucidated. In the present study, the computerized tomography (CT) scans of patients receiving mTOR inhibitors for at least 6 months taken at baseline and post‑therapy were retrospectively retrieved, and body composition analyses were performed using the software, sliceOmatic version 5.0 (TomoVision, Inc., Magog, QC, Canada). The difference in body composition parameters was evaluated for significance. The time to treatment (TTF) failure was also compared between the sarcopenic and non-sarcopenic patients at the baseline. Of the 75 patients studied, 20 matched the inclusion criteria (including 16 males). The mean duration between the CT scans was 14.4±2.0 months. A total of 12 (60%) patients were sarcopenic at the baseline, whereas three more (75% in total) became sarcopenic following treatment. The use of mTOR inhibitors significantly decreased the skeletal muscle area (P=0.011) and lean body mass (P=0.007), although it had no effect on adipose tissue (P=0.163) or body weight (P=0.262). The rate of skeletal muscle wasting was 2.6 cm2/m2, or 2.3 kg in 6 months. The TTF did not differ between sarcopenic and non‑sarcopenic patients, and was not significantly associated with any other parameter. To the best of our knowledge, this is the first study to demonstrate that the long‑term use of mTOR inhibitors induces a marked loss of muscle mass. Due to the predictive and prognostic role of sarcopenia in cancer patients, these findings may have important clinical implications.
View Figures
View References

Related Articles

Journal Cover

November 2016
Volume 5 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gyawali, B., Shimokata, T., Honda, K., Kondoh, C., Hayashi, N., Yoshino, Y. ... Ando, Y. (2016). Muscle wasting associated with the long-term use of mTOR inhibitors. Molecular and Clinical Oncology, 5, 641-646. https://doi.org/10.3892/mco.2016.1015
MLA
Gyawali, B., Shimokata, T., Honda, K., Kondoh, C., Hayashi, N., Yoshino, Y., Sassa, N., Nakano, Y., Gotoh, M., Ando, Y."Muscle wasting associated with the long-term use of mTOR inhibitors". Molecular and Clinical Oncology 5.5 (2016): 641-646.
Chicago
Gyawali, B., Shimokata, T., Honda, K., Kondoh, C., Hayashi, N., Yoshino, Y., Sassa, N., Nakano, Y., Gotoh, M., Ando, Y."Muscle wasting associated with the long-term use of mTOR inhibitors". Molecular and Clinical Oncology 5, no. 5 (2016): 641-646. https://doi.org/10.3892/mco.2016.1015